JPMorgan Chase & Co. Has $15.19 Million Position in Bruker Co. (NASDAQ:BRKR)

JPMorgan Chase & Co. trimmed its holdings in shares of Bruker Co. (NASDAQ:BRKR) by 6.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219,884 shares of the medical research company’s stock after selling 15,857 shares during the period. JPMorgan Chase & Co.’s holdings in Bruker were worth $15,185,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. True Wealth Design LLC raised its holdings in Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares in the last quarter. UMB Bank n.a. increased its position in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock worth $46,000 after purchasing an additional 354 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Bruker during the 2nd quarter worth approximately $52,000. GAMMA Investing LLC boosted its holdings in shares of Bruker by 81.0% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after buying an additional 388 shares during the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Bruker in the third quarter valued at $73,000. Institutional investors own 79.52% of the company’s stock.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien bought 100,000 shares of Bruker stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the acquisition, the chief executive officer now owns 38,439,563 shares in the company, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 28.30% of the company’s stock.

Bruker Stock Performance

NASDAQ:BRKR opened at $60.78 on Friday. The stock has a 50 day simple moving average of $57.77 and a 200 day simple moving average of $61.85. The stock has a market cap of $9.21 billion, a P/E ratio of 29.22, a PEG ratio of 4.00 and a beta of 1.17. Bruker Co. has a 1-year low of $48.07 and a 1-year high of $94.86. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. During the same period in the prior year, the business posted $0.74 EPS. The firm’s quarterly revenue was up 16.4% compared to the same quarter last year. Research analysts anticipate that Bruker Co. will post 2.4 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 16th. Shareholders of record on Monday, December 2nd were given a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.33%. Bruker’s payout ratio is presently 9.62%.

Wall Street Analysts Forecast Growth

BRKR has been the topic of several analyst reports. Guggenheim began coverage on shares of Bruker in a research note on Thursday, December 19th. They issued a “buy” rating and a $72.00 price target for the company. Bank of America raised their target price on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research note on Friday, December 13th. Wolfe Research downgraded Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Citigroup cut their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Finally, UBS Group assumed coverage on Bruker in a research note on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price for the company. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $74.45.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.